Commerzbank Aktiengesellschaft’s Juno Therapeutics, Inc. JUNO Stock Holding History

Commerzbank Aktiengesellschaft’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-10,181	Closed	-$192K	–	1027
2016 Q4	$192K	Buy	+10,181	New	+$249K	﹤0.01%	912
2015 Q3	–	Sell	-15,174	Closed	-$809K	–	1211
2015 Q2	$809K	Buy	+15,174	New	+$805K	﹤0.01%	873

Other funds holding JUNO

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BCM

Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Commerzbank Aktiengesellschaft's JUNO Position: Q1 2017 in Review

Commerzbank Aktiengesellschaft sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2017, closing a stake of 10,181 shares — an estimated $192K sold.

Commerzbank Aktiengesellschaft first reported a position in JUNO in Q2 2015 and held it in 2 quarters. The position peaked at $809K in Q2 2015. 157 funds tracked by Wall St. Rank hold JUNO as of Q1 2017.

Commerzbank Aktiengesellschaft reported no remaining Juno Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
Commerzbank Aktiengesellschaft sold 10,181 Juno Therapeutics, Inc. shares in Q1 2017, an estimated $192K.
Commerzbank Aktiengesellschaft first reported a position in Juno Therapeutics, Inc. in Q2 2015 and held it in 2 quarters.
Commerzbank Aktiengesellschaft's Juno Therapeutics, Inc. position peaked at $809K in Q2 2015.
157 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2017.

Based on Commerzbank Aktiengesellschaft's 13F filing for Q1 2017, filed 1 May 2017.